Founder, C-suite executive and Board member with global team, company-building, product launch and fundraising experience. Developed and executed strategies supporting clinical development, FDA/EMA approval, and commercial launch of multiple products in specialty therapeutic areas across modalities.

Delivered results with a passion developed over a 25+ year career dedicated to improving the survival and quality of life for grievously ill patients suffering from rare, intractable, and fatal diseases.

♦ Founded a cell therapy company, Cellevolve Bio, in 2020 and executed on 3 critical partnerships, while preparing for its first pivotal clinical trial in PML, a rare yet often fatal neurodegenerative disease.

♦ Re-structured R&D and manufacturing company to a fully integrated cell therapy player planning to launch a 1st-of-its-kind therapeutic, building its commercial organization from the ground up.

♦ Turned around an underperforming organization that was critical to the company’s future direction and prepared it for the transition beyond anti-virals, exemplified by revenue growth from $11B in 2013 to $30+B in 2016. Led launch for 8 approved products, including the company’s 1st oncology therapeutic.

♦ Positioned spun-off company to launch its 1st oncology product by developing its overall R&D, TA strategy and commercialization approach.

♦ Successfully managed P&Ls at both the team and business unit levels in specialty markets.

♦ Key member of 20+ B&D teams that resulted in multiple licensed products and acquisitions, including offer for Medivation, Kite Pharma acquisition, filgotinib/RA from Galalpagos, and Immunex, among others.

♦ Board Memberships: Passage Bio (NASDAQ: PASG), a CNS focused gene therapy company. Audit Committee and Nomination and Governance Committee member. Portal Innovations, a life sciences venture development engine incubator. Medical Alumni Advisory Committee, University of Pennsylvania Perelman School of Medicine.